Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Condition:   Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Interventions:   Drug: Empagliflozin;   Drug: olanzapine Sponsor:   Tanta University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials